All News
Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis
A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use.
Read Article
No Risk of Interstitial Lung Disease with Methotrexate Use
JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).
Read Article
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/oW6NBjIG7E https://t.co/toyvHxJlr9
Dr. John Cush RheumNow ( View Tweet)
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
data now out to 60w
good humoral and cellular response in most, even without MTX withheld
(& good safety too)
Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 Rheumatology Roundup
Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna
https://t.co/TqEAuk0PGp https://t.co/erRZ3cLxhu
Dr. John Cush RheumNow ( View Tweet)
SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085
Dr. John Cush RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question
Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria.
https://t.co/xA8YYCi94r https://t.co/RyS6vnlzam
Dr. John Cush RheumNow ( View Tweet)
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024
Dr. John Cush RheumNow ( View Tweet)
Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/NUZ3cc4bUx https://t.co/nGP10y3Kuw
Dr. John Cush RheumNow ( View Tweet)
BiTEs (Bispecific T cell engagers) kill B cells by engaging T cells. IV blinatumomab (CD19xCD3 BiTE) rx of 6 refractory RA pts, led to B & T cell depletion, rapid decline Dz activity, synovitis, autoAbs & was safe, w/ brief temp & ^CrP w/ 1st rx https://t.co/ebLsknirtQ https://t.co/eEIch4g0I1
Dr. John Cush RheumNow ( View Tweet)
9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024
Dr. John Cush RheumNow ( View Tweet)
Tapering Treatment for Lupus
Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus.
https://t.co/ijy5OwIoCe https://t.co/7yQIxW70Zd
Dr. John Cush RheumNow ( View Tweet)
Cognitive Function in Older Adults: Worse in Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
https://t.co/zedGdNbHw4 https://t.co/DIHvkEZRVk
Dr. John Cush RheumNow ( View Tweet)
A Puzzling Era in Global Drug Development?
Dr. Eric Ruderman offers his observation regarding a puzzling global drug development observation, at Eular 2024 in Vienna, Austria.
https://t.co/A4KQovIt3u https://t.co/TQHJnSkIod
Dr. John Cush RheumNow ( View Tweet)
Be-GIANT cohort, 44.3% pts met definition of early axSpA (<2 yr Sxs). early axSpA had younger age and lower frequency of radiographic sacroiliitis. MDs think early disease to be more severe with higher physician global than late axSpA @synovialjoints #EULAR2024 Abstract POS0443 https://t.co/97J9tg0XZg
Dr. John Cush RheumNow ( View Tweet)
FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw
Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG
Dr. John Cush RheumNow ( View Tweet)
Work ability impaired in majority of axSpA measured by the WAI score. 996 pts w a mean WAI score of 31.7. Overall, 28%/43%pts were in poor/moderate work ability, older, more often obese, w/ lower education, & phys work @synovialjoints #EULAR2024 Abstract POS0437
@RheumNow https://t.co/rQ4BunCn6T
Dr. John Cush RheumNow ( View Tweet)
Systemic Score in AOSD to Predict Life-threatening Complications
Dr. Bella Mehta discusses abstract OP0001 presented at Eular 2024 in Vienna, Austria.
https://t.co/Vw9prpAqKd https://t.co/RhGhDuJ8b2
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f
Dr. John Cush RheumNow ( View Tweet)